McArthur G - Search Results

1

Applications of positron emission tomography in the development of molecular targeted cancer therapeutics.

Solomon B, McArthur G, Cullinane C, Zalcberg J, Hicks R. Solomon B, et al. Among authors: mcarthur g. BioDrugs. 2003;17(5):339-54. doi: 10.2165/00063030-200317050-00004. BioDrugs. 2003. PMID: 14498764 Review.

2

EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.

Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. Solomon B, et al. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):713-23. doi: 10.1016/s0360-3016(02)04357-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12573759

3

Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.

Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ. Solomon B, et al. Mol Cancer Ther. 2005 Sep;4(9):1417-22. doi: 10.1158/1535-7163.MCT-05-0066. Mol Cancer Ther. 2005. PMID: 16170034

4

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.

Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM. Cullinane C, et al. Cancer Res. 2005 Nov 1;65(21):9633-6. doi: 10.1158/0008-5472.CAN-05-2285. Cancer Res. 2005. PMID: 16266981 Free article.

5

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.

Dorow DS, Cullinane C, Conus N, Roselt P, Binns D, McCarthy TJ, McArthur GA, Hicks RJ. Dorow DS, et al. Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):441-52. doi: 10.1007/s00259-005-0039-5. Epub 2006 Feb 1. Eur J Nucl Med Mol Imaging. 2006. PMID: 16450138

6

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.

Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM. Loughrey MB, et al. Among authors: mcarthur ga. Histopathology. 2006 Jul;49(1):52-65. doi: 10.1111/j.1365-2559.2006.02464.x. Histopathology. 2006. PMID: 16842246

7

The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.

Khamly KK, Hicks RJ, McArthur GA, Thomas DM. Khamly KK, et al. Expert Rev Mol Diagn. 2008 Jan;8(1):105-19. doi: 10.1586/14737159.8.1.105. Expert Rev Mol Diagn. 2008. PMID: 18088235 Review.

8

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.

Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D. Dawson SJ, et al. Among authors: mcarthur g. Anticancer Drugs. 2008 Jun;19(5):547-52. doi: 10.1097/CAD.0b013e3282fc6cf7. Anticancer Drugs. 2008. PMID: 18418222

9

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.

Cullinane C, Natoli A, Hui Y, Conus N, Jackson S, Brüggen J, Manley PW, McArthur GA. Cullinane C, et al. Mol Cancer Ther. 2010 May;9(5):1461-8. doi: 10.1158/1535-7163.MCT-09-1181. Epub 2010 May 4. Mol Cancer Ther. 2010. PMID: 20442311

10

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.

Aide N, Kinross K, Cullinane C, Roselt P, Waldeck K, Neels O, Dorow D, McArthur G, Hicks RJ. Aide N, et al. Among authors: mcarthur g. J Nucl Med. 2010 Oct;51(10):1559-64. doi: 10.2967/jnumed.109.073288. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847160 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

451 results

Search Page

Filters